Elucidating the cellular and molecular basis of fibroinflammation
Active Grant Awarded Last action
- Award ID
- R56AR087127
- Recipient
-
The Regents Of The University Of California. San Francisco UEI KMH5K9V7S518
- Awarding agency
-
National Insititue of Arthritis and Musculoskeletal and Skin Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $300,000
Award facts
- Assistance listing
- 93.846 Arthritis, Musculoskeletal and Skin Diseases Research
- Completion date 21% complete
- Place of performance
- San Francisco, CA 94143, USA
Award details come from USAspending.gov.
About this award
The National Institute of Arthritis and Musculoskeletal and Skin Diseases, within the National Institutes of Health and the Department of Health and Human Services, awarded The Regents of the University of California, San Francisco a $300,000 grant on September 9, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The program supports research into the causes, treatment, and prevention of arthritis and musculoskeletal and skin diseases.
Grant R56AR087127 funds research into fibroinflammation, the tissue inflammation associated with fibrosing skin diseases. The project examines how CD8+ T cells and PI16-expressing fibroblasts (PIFs) contribute to it. The investigators hypothesize that CD8+ T cells kill adipocytes, directly or through cytokine secretion, when tissue immune regulation is reduced, and that type 1 and type 2 immune responses drive PIFs toward a pro-inflammatory and pro-fibrotic state. They will test these hypotheses in a novel murine model of skin fibroinflammation produced by a transient reduction in regulatory T cells early in life. The project also uses a newly generated transgenic mouse strain to study PIF biology and the inflammatory pathways that activate these cells.
Place of performance is San Francisco, California 94143. The ultimate completion date is August 31, 2027. The assistance type is a grant.
Description
- Abstract
- Fibrosing diseases of the skin are highly morbid conditions with a large unmet medical need. These diseases are strongly associated with tissue inflammation (termed 'fibroinflammation'). IT is thought that both the quality and quantity of these inflammatory reactions play a major role in dictating whether fibrosis will occur and how severe IT will be. The cellular and molecular pathways that drive fibroinflammation remain to be fully elucidated. We have discovered that CD8+ T cells play a major role in driving fibroinflammation. In addition, we have identified a novel population of skin fibroblasts that are highly responsive to inflammatory cytokines and rapidly expand in this context. The central focus of this grant application is to elucidate the cellular and molecular mechanisms by which CD8+ T cells and the newly discovered PI16 expressing fibroblasts (PIFS) contribute to fibroinflammation. We hypothesize that when there is a reduction in tissue immune regulation, CD8+ T cells kill adipocytes, either directly through adipocyte-specific antigen recognition or indirectly through secretion of cytokines that adipocytes are exquisitely sensitive to. We further hypothesize that in this setting, both type 1 and type 2 immune responses activate PIFS and drive them towards a pro-inflammatory and pro-fibrotic state. The combination of adipocyte death and activation of PIFS work in concert to create a unique microenvironment that facilitates pro-fibrotic inflammation. These hypotheses will be tested using a novel murine model of skin fibroinflammation resulting from a transient reduction in regulatory T cells (TREGS) early in life. In addition, we have generated a new transgenic mouse strain to interrogate the fundamental biology of PIFS, with a focus on discerning the inflammatory pathways responsible for activating these cells. We employ innovative and cutting-edge methodology to test our hypotheses, including skin specific genetic manipulation of immune cells and an adeno-associated virus (AAV) system to selectively genetically modify PIFS. Through these lines of investigation, we will achieve a better understanding of the pathways that drive pro-fibrotic inflammation in attempts to inform novel treatment strategies targeting fibrosing diseases at the fibroinflammatory stage, possibly halting progression to fulminant organ fibrosis.
Quick answers
Who received award R56AR087127?
R56AR087127 was awarded to The Regents Of The University Of California. San Francisco by National Insititue of Arthritis and Musculoskeletal and Skin Diseases (National Institutes of Health) on September 9, 2026.
How much is award R56AR087127 worth?
$300,000 has been obligated on R56AR087127.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award